US EditionMorepen Labs' Facility Clears USFDA Inspection with NIL Adverse Observation for the Record Fourth Consecutive Time
3 Articles
3 Articles
Morepen Labs' Facility Clears USFDA Inspection with NIL Adverse Observation for the Record Fourth Consecutive Time
Get latest articles and stories on Business at LatestLY. Gurugram (Haryana) [India], April 20: Morepen Laboratories Limited (NSE: MOREPENLAB; BSE: 500288) has announced the successful completion of a USFDA (United States Food and Drug Administration) inspection at its Masulakhanna (Himachal) facility, with Zero adverse observations (No Form 483 issued by the drug regulator). This marks the Fourth consecutive NIL 483 USFDA inspection for Morepen …
The company has set a new standard in pharmaceutical excellence, further strengthening its global leadership in quality and regulatory compliance. Gurugram, Haryana. Morepen Laboratories Limited (NSE: MOREPENLAB; BSE: 500288) has successfully passed the USFDA (US Food and Drug Administration) inspection at its manufacturing facility in Masulkhana, Himachal Pradesh. The inspection revealed no adverse observations, meaning the regulatory body did …
Morepen Laboratories clears fourth USFDA inspection at Masulkhana facility with NIL 483
Morepen Laboratories announced that it has cleared its fourth consecutive inspection by the United States Food and Drug Administration at its Masulkhana facility with zero observations and no Form 483 issued. The company stated that the milestone follows a multi-year contract development and manufacturing organisation mandate valued at approximately Rs 825 crore (USD 91 million) from a global pharmaceutical company. Sushil Suri, Chairman and Man…
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
